Mumbai/Delhi and Singapore – 24th February 2025

Agilus Diagnostics, India’s largest diagnostics company and Lucence, a global pioneering molecular diagnostics company, announced today that they have entered into a strategic collaboration to advance cancer diagnostics and personalised medicine in India. This collaboration will integrate Lucence’s cutting-edge molecular testing technologies into Agilus’ extensive laboratory network, offering enhanced cancer detection, treatment selection, and monitoring capabilities.

Through this collaboration, Agilus Diagnostics will integrate Lucence’s advanced molecular testing solutions into its comprehensive oncology diagnostics portfolio. LiquidHALLMARK® is an ultra-sensitive, next-generation sequencing liquid biopsy that analyzes circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) for clinically relevant biomarkers across various cancers. LiquidHALLMARK® profiles actionable somatic mutations in 80 ctDNA genes and 37 ctRNA fusions.

“At Agilus Diagnostics, we are committed to advancing diagnostic excellence through innovation and strategic collaborations. Our collaboration with Lucence strengthens our ability to provide world-class cancer diagnostics, offering oncologists and patients access to precision-driven solutions,” said Dr. Anand K, Managing Director & CEO at Agilus Diagnostics. India, a country with 1.43 billion people, sees 1.46 million cancer patients and 916,000 deaths from cancer annually.

Lucence’s proprietary technology will empower Agilus Diagnostics to expand its oncology capabilities, offering liquid biopsy-based screening for early cancer detection, recurrence monitoring, and therapy personalization. By integrating these pioneering tests into its extensive network of laboratories, Agilus Diagnostics aims to enhance accessibility of precision oncology across India.

“Lucence is dedicated to transforming cancer care with non-invasive, highly accurate genomic tests. This collaboration with Agilus Diagnostics allows us to scale our impact and bring the benefits of precision oncology to a larger patient population in India,” said Tan Min-Han, M.B.B.S., F.R.C.P., Ph.D., Founding CEO and Medical Director of Lucence.

This collaboration aligns with Agilus Diagnostics’ mission to harness technological advancements in laboratory medicine, ensuring that Indian patients and healthcare providers have access to world-class diagnostic solutions.

About Agilus Diagnostics

Agilus Diagnostics is a leading healthcare service provider in India, specializing in diagnostic and pathology services. The company offers a broad range of services, including pathology tests, imaging, and radiology, with a focus on accuracy, reliability, and quick results. With a network of diagnostic centres across India, Agilus Diagnostics strives to make healthcare more accessible and affordable, ensuring timely and efficient care for patients.

About Lucence

Lucence is a precision oncology company committed to improving cancer care through innovative testing solutions. With CLIA-licensed and CAP-accredited laboratories in California and Singapore, Lucence offers advanced liquid biopsy technologies that provide critical insights into cancer biology. The company’s flagship product, LiquidHALLMARK®, is designed to detect clinically relevant biomarkers in ctDNA and ctRNA, enabling precise and personalized cancer treatment.

Media Contacts:

Agilus Diagnostics: madhav.maharaj@agilus.in

Lucence: inquiry@lucence.com